Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger sequencing (SS) is recommended before changing therapy since detection of specific mutations influences second-generation t...

Descripción completa

Detalles Bibliográficos
Autores principales: Soverini, Simona, De Benedittis, Caterina, Polakova, Katerina Machova, Linhartova, Jana, Castagnetti, Fausto, Gugliotta, Gabriele, Papayannidis, Cristina, Mancini, Manuela, Klamova, Hana, Salvucci, Marzia, Crugnola, Monica, Iurlo, Alessandra, Albano, Francesco, Russo, Domenico, Rosti, Gianantonio, Cavo, Michele, Baccarani, Michele, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008338/
https://www.ncbi.nlm.nih.gov/pubmed/26980736
http://dx.doi.org/10.18632/oncotarget.8010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008338/
https://www.ncbi.nlm.nih.gov/pubmed/26980736
http://dx.doi.org/10.18632/oncotarget.8010

Ejemplares similares